29th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220226459 | DOSAGE REGIMENS FOR VACCINES - The present invention relates to immunogenic therapies for the treatment or prevention of a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection. | 2022-07-21 |
20220226460 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES - This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses. | 2022-07-21 |
20220226461 | Nucleoside-modified RNA for Inducing an Adaptive Immune Response - The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. | 2022-07-21 |
20220226462 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE - Provided herein is a method for preventing a person from an infection by a Coronaviridae virus with a poliomyelitis vaccine. Also provided herein is a method of inducing a protective immune response against a Coronaviridae virus with a poliomyelitis vaccine. | 2022-07-21 |
20220226463 | RECOMBINANT NON-STRUCTURAL PROTEIN 1, RECOMBINANT INFLUENZA VIRUS AND IMMUNOLOGICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF TREATING OR PREVENTING DISEASE OR CONDITION CAUSED BY OR ASSOCIATED WITH INFLUENZA VIRUS - The present invention relates to a recombinant nonstructural protein 1 (NS 1), a recombinant influenza virus and an immunological composition including the same, as well as a method of treating or preventing a disease or condition caused by or associated with an influenza virus in a subject in need thereof. At least one amino acid residue is mutated or deleted in 4 contiguous amino acid residues of TRAF3-interacting motifs (TIMs) within an effector domain of the recombinant NS 1. A recombinant influenza virus including the recombinant NS1 is comparable to the wild-type influenza virus in virus replication ability, and the recombinant influenza virus can elevate interferon activation of a subject for achieving better immune response and better immunological protection, leading in a method of treating or preventing a disease or condition caused by or associated with an influenza virus in a subject in need thereof. | 2022-07-21 |
20220226464 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNE RESPONSES - A method of modulating immune response to an infection in a subject, the method comprising contacting CD4+ T cells, monocytes, cytotoxic lymphocytes (CTLs), natural killer (NK) cells, and/or proliferating T cells in the subject with one or more modulating agents, wherein the one or more modulating agents modulate genes in one or more of pathways and cell populations. | 2022-07-21 |
20220226465 | Coronavirus Immunogenic Compositions, Methods and Uses Thereof - The present specification discloses broad-spectrum, pan-Coronavirus immunogenic composition including amino acid-based, broad-spectrum, pan-Coronavirus immunogenic compositions and nucleotide-based, broad-spectrum, pan-Coronavirus immunogenic compositions, methods and uses for preventing or treating a Coronavirinae-based infection or pathology as well as methods and uses of creating, maintaining or restoring antigenic memory to one or more Coronavirus species, strains, genotypes, subgenotypes, serotypes or genetic/antigenic lineages in an individual or population of individuals. | 2022-07-21 |
20220226466 | PHARMACEUTICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2 - The invention relates to biotechnology. The claimed agent can be used for the prevention of SARS-CoV-2. | 2022-07-21 |
20220226467 | ARENAVIRUS VECTORS FOR HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOF - Arenavirus vectors encoding hepatitis B virus (HBV) vaccines are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed arenavirus vectors are also described. | 2022-07-21 |
20220226468 | PYRIMIDINE COMPOUND - The present invention provides a compound of the formula (1): | 2022-07-21 |
20220226469 | THERAPEUTIC SIRP-ALPHA ANTIBODIES - Anti-SIRPα monoclonal antibodies (anti-SIRPα mAbs), including multispecific SIRPα antibodies, are provided with distinct functional profiles as are related compositions and methods of using anti-SIRPα mAbs as therapeutics for the prevention and treatment of solid and hematological cancers. Also provided are amino acid sequences of exemplary anti-SIRPα monoclonal antibodies. | 2022-07-21 |
20220226470 | ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION - The present invention provides antibodies that neutralize infection of influenza A virus. The invention also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies. In addition, the invention provides the use of the antibodies of the invention in prophylaxis and treatment influenza A infection. | 2022-07-21 |
20220226471 | SONOSENSITIZATION - An improved method for MRI-guided sonosensitized focused ultrasound treatment of malignant tissue is disclosed herein. | 2022-07-21 |
20220226472 | Antimicrobial Quantum Dots and Methods of Tuning the Same - The present disclosure relates in one aspect to compositions containing indium phosphide (InP) or ternary zinc cadmium telluride (Zn | 2022-07-21 |
20220226473 | Nucleic acid nanocarrier drug and preparation method thereof, pharmaceutical composition and application thereof - Provided are a nucleic acid nanocarrier drug, a preparation method thereof, a pharmaceutical composition and an application thereof. The drug includes nucleic acid nanoparticle and a drug, the drug is loaded on the nucleic acid nanoparticle, and the drug includes one or more of tacrine, epirubicin, methotrexate, pirarubicin, daunorubicin, pentafluorouracil, 10-hydroxycamptothecin, aspirin and gemcitabine; and the nucleic acid nanoparticle includes a nucleic acid domain including a sequence a, a sequence b and a sequence c, the sequence a includes a sequence a1 or a sequence obtained by insertion, deletion or substitution at least one base in the sequence a1, the sequence b includes a sequence b1 or a sequence obtained by insertion, deletion or substitution at least one base in the sequence b1, and the sequence c includes a sequence c1 or a sequence obtained by insertion, deletion or substitution at least one base in the sequence c1. | 2022-07-21 |
20220226474 | ANTI-FUGETACTIC AGENT AND ANTI-CANCER AGENT COMBINATION THERAPY AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent. | 2022-07-21 |
20220226475 | WATER-ACTIVATED MUCOADHESIVE COMPOSITIONS AND METHODS OF DELIVERING BIOLOGICALLY ACTIVE SUBSTANCES - This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents and one or more biologically active substances to mucosal surfaces within the GI tract and methods for the manufacture and the use of these compositions. | 2022-07-21 |
20220226476 | NANOPARTICLES AND METHODS FOR PREPARATION THEREOF - The invention provides a nano-sized particle comprising a cross-linked polymer, wherein the polymer is selected from the group consisting of a polyacrylic acid homopolymer; polymethacrylic acid homopolymer; poly(alkylcyanoacrylate) polymer; a copolymer comprising at least two monomers selected from acrylic acid, methacrylic acid, hydroxyethyl acrylate, hydroxyethyl methacrylate, and alkyl cyanoacrylate/cyanoacrylic acid monomers; carboxymethyl cellulose; alginic acid polymer, polylactic-polyglycolic acid (PLGA), and xanthan gum; and wherein said polymer is cross-linked with a metal ion. A process for preparing such particles is also provided. | 2022-07-21 |
20220226477 | THE USE OF LOW MOLECULAR WEIGHT POLYVINYLPYRROLIDONE (PVP) TO REDUCE VISCOSITY OF HIGH CONCENTRATION PROTEIN FORMULATIONS - Disclosed herein are pharmaceutical compositions (formulations) having reduced viscosity, using a low molecular weight polyvinylpyrrolidone (povidone) in the case of high therapeutic protein concentration (≥70 mg/ml) formulations. The addition of arginine, such as arginine monohydrochloride or N-acetyl arginine, can further reduce viscosity. Appropriate therapeutic proteins include antibodies, such as monoclonal antibodies, and derivatives, fragments, and analogues thereof. | 2022-07-21 |
20220226478 | FILM-FORMING COMPOSITION CONTAINING GELLAN GUM AND STARCH, AND APPLICATION IN SOFT CAPSULE - Provided is a starch film-forming composition, comprising: A, a first gelling agent; B, starch; C, a plasticizer; D, water; wherein the first gelling agent is a gellan gum with two gel temperatures, wherein the first gel temperature is 51 to 75° C. and the second gel temperature is 40° C. to 50° C. The present application relates to the field of food or pharmaceutical raw materials. The composition is obviously superior to the prior art in terms of rubber strength, toughness and forming bonding when used in preparation of soft capsules, can fully meet the requirements for industrial production of soft capsules and can be used as an alternative in soft capsule technology. | 2022-07-21 |
20220226479 | CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION - There is provided technology for promoting permeation of a substance into a cell layer. Provided is a cell layer permeation promoter comprising a compound represented by general formula (1). Also provided is a composition for facilitating drug absorption that contains the cell layer permeation promoter, said composition being for facilitating absorption of a drug into a living body. Also provided is a pharmaceutical composition that contains the cell layer permeation promoter and furthermore contains a drug to be absorbed into a living body. | 2022-07-21 |
20220226480 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY - The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (IId): -L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6 and wherein L comprises 5 to 40 carbon atoms and 0 to 2 carbon-carbon double bonds. The lipid conjugate can p be formulated in a drug delivery vehicle such as a lipid nanoparticle (LNP). | 2022-07-21 |
20220226481 | DEGRADATION OF AKT BY CONJUGATION OF ATP-COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE - Disclosed are bifunctional compounds comprising a GDC-0068 analog that binds AKT isoforms AKT1, 2 and 3, pharmaceutical compositions, and methods for treating diseases or conditions mediated by dysfunctional AKT activity. | 2022-07-21 |
20220226482 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS - Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed. | 2022-07-21 |
20220226483 | DRUG-POLYMER CONJUGATE - A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R | 2022-07-21 |
20220226484 | THERAPEUTIC PEPTIDES - The disclosures herein relate to the fields of cell biology and the modulation of cellular mechanisms controlling cell viability, cell proliferation, and metabolic processes. More specifically disclosed herein are peptides effective to modulate cellular mechanisms controlling cell viability, cell proliferation, and metabolic processes, including cell signaling associated with aberrant cellular proliferation and malignancy. Also disclosed herein are peptides effective in modulating cellular mechanisms controlling cell viability, treating metabolic diseases, and as cytoprotective agents. Also disclosed are peptides effective in the treatment of fibrosis. | 2022-07-21 |
20220226485 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) - The present disclosure provides a chimeric polypeptide comprising a helical bundle which comprises between about two and about seven alpha-helices and a bioactive peptide, wherein one or more of the alpha helices form one or more inter-helix hydrogen bonds and comprise at least one phosphorylation site and wherein the bioactive peptide is conformationally placed inside the helical bundle so that the bioactive peptide is not activated or exposed. The disclosure also provides a nucleotide sequence encoding the chimeric polypeptide, a vector comprising the nucleotide sequence, a cell comprising the nucleotide sequence, and method of making, using, or designing the chimeric polypeptide. | 2022-07-21 |
20220226486 | SYNTHETIC COMPOUND - The present invention relates to a synthetic compound comprising at least one effector moiety and at least one binder moiety, wherein the effector moiety is associated to the binder moiety, and wherein further the effector moiety comprises a N-formyl methionine peptide which comprises an isoleucine residue. | 2022-07-21 |
20220226487 | A PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER - Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer. | 2022-07-21 |
20220226488 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES - Disclosed herein are Trastuzumab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzumab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzumab-linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use. | 2022-07-21 |
20220226489 | THERAPEUTICS DIRECTED AGAINST CORONAVIRUS - This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering one or more polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as, for example, SARS-CoV-1, SARS-CoV-2 or a variant thereof. It is contemplated that the polypeptide can be linked to an amino acid, wherein the compound extends the serum half-life of the amino acid. | 2022-07-21 |
20220226490 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates - The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first cleavable moiety and a second cleavable moiety that hinders cleavage of the first cleavable moiety. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. | 2022-07-21 |
20220226491 | Immunoconjugates Targeting PD-L1 - The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate. | 2022-07-21 |
20220226492 | Immunoconjugates Targeting HER2 - The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate. | 2022-07-21 |
20220226493 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF - Antibody-drug conjugates (ADCs) comprising an anthracycline and an anti-CD117 antibody are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided. | 2022-07-21 |
20220226494 | Anti-EGFR Antibody-Drug Conjugates - The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs. | 2022-07-21 |
20220226495 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION - Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes. | 2022-07-21 |
20220226496 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE - The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy. | 2022-07-21 |
20220226497 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE - A method for producing a compound represented by formula (C) wherein R | 2022-07-21 |
20220226498 | SUBSTRATE DELIVERY OF EMBEDDED LIPOSOMES - This invention relates to compositions useful for localized and sustained release of therapeutic agents, and more particularly to functionalized liposomes embedded in a polyelectrolyte multilayer. Methods of preparing the compositions, methods of treating diseases, devices, and pharmaceutical compositions comprising the compositions are also provided. | 2022-07-21 |
20220226499 | Metabolite Delivery for Modulating Metabolic Pathways of Cells - The present disclosure provides metabolite-based polymeric particles and methods for a modulating the intracellular metabolic-profile/pathways. For example, in one aspect, the disclosure relates to alpha-ketoglutarate (aKG)-based polymeric-microparticles and methods of use. | 2022-07-21 |
20220226500 | FULLERENIC ELLAGIC LUTEOLIN AND METHODS - A nanoparticle composition of buckminsterfullerene with ellagic acid is provided that becomes substantially more efficacious to maintain or re-establish benign healthy cellular homeostasis with the functionalization of at least about 10% luteolin. This composition is formulated to prevent or to treat chronic obstructive pulmonary disorder (COPD). In addition, the ability to penetrate hydrophobic malignant tissues via desulfurization is promoted with the addition of phosphonate pendant groups. This further enables the composition to penetrate fungal spores, the hydrophobic regions of uncontrolled cellular proliferation, neoplasms, degenerative malignancy, and to help treat chronic inflammatory diseases associated with or leading to induce cancer in susceptible cells. The composition can be produced at low temperatures through reactive shear milling. Delivery methods include ingestion, topical application, topical buccal application, inhalation, or injection when used as a medicament or as a food supplement. | 2022-07-21 |
20220226501 | Insulin gene therapy - Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith. | 2022-07-21 |
20220226502 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF CYSTATHIONINE BETA-SYNTHASE (CBS) ENZYME FOR TREATING CBS DEFICIENCY - The present disclosure provides enzyme replacement therapy using gene therapy vectors, such as adeno-associated virus (AAV) vectors expressing human Cystathionine Beta-Synthase (CBS) to reduce the amount of serum homocysteine (Hcy) and increase the amount of downstream metabolites, such as cystathionine and cysteine (Cys), which can be used for treatment of diseases, such as homocystinuria and homocysteine remethylation disorders. | 2022-07-21 |
20220226503 | METHODS FOR EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES IN VITRO AND IN VIVO - Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target. | 2022-07-21 |
20220226504 | COMPOSITION FOR TREATMENT OF CRIGLER-NAJJAR SYNDROME - The invention provides a polynucleotide sequence (e.g., a gene, e.g., DNA or RNA) encoding UGT1A1 (e.g., expressing human UGT1A1). The invention further provides a vector, such as an adeno-associated virus (AAV) vector (e.g., AAV8) having a vector genome including inverted terminal repeat sequences and a UGT1A1 coding sequence operably linked to one or more expression control sequences (e.g., expression control sequences including a liver-specific promoter). Also provided are compositions containing these AAV vectors and methods of treating Crigler-Nijjar syndrome type I, Crigler-Nijjar syndrome type II, and Gilbert syndrome. | 2022-07-21 |
20220226505 | DNA, EXPRESSION VECTOR, TRANSCRIPT, CELL, PHARMACEUTICAL COMPOSITION, AND MEDICINE - An object of the invention is to provide a novel pharmaceutical composition. The pharmaceutical composition of the disclosure contains a DNA encoding a suicide gene having at least one intron sequence. The intron sequence has a donor sequence or an acceptor sequence to be used in a tumor cell with abnormal splicing not in a normal cell. In a transcript of the DNA, the suicide gene is expressed when the intron is abnormally spliced and the suicide gene is not expressed when the intron is not abnormally spliced. | 2022-07-21 |
20220226506 | EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS - The present invention relates to a polynucleotide comprising at least one promoter, at least one expressible construct, and an S/MAR element, wherein said polynucleotide is an integration construct or a non-integrative vector construct, wherein said S/MAR element is located downstream of said promoter and of said expressible construct, and wherein said S/MAR element is flanked by a splice donor and a splice acceptor. The present invention also relates to a composition and a host cell comprising said polynucleotide, as well as to uses and methods related thereto. | 2022-07-21 |
20220226507 | OPTIMIZED GENE THERAPY TARGETING RETINAL CELLS - The present disclosure relates to methods of targeting specific cell types within the retina using optimized gene therapy vectors. In particular, the disclosure provides gene therapy vectors to specifically target retinal cells and methods of treating visual impairment, retinal degeneration and vision-related disorders such as CLN disease. | 2022-07-21 |
20220226508 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY - Provided, inter alia, are methods and compositions for treating epilepsy. In one aspect, provided herein is a method of selecting a compound for treating epilepsy, said method includes, contacting a test compound with 5-hydroxytryptamine-2B receptor (5-HT2B), and measuring the 5-HT2B agonistic activity of the test compound. In another aspect, provided herein is a method of treating an epilepsy in a subject in need thereof. The method includes administering to said subject an effective amount of a 5-HT2B specific receptor agonist. | 2022-07-21 |
20220226509 | HIGH-BRIGHTNESS NANODOT FLUOROPHORES BY COVALENT FUNCTIONALIZATION - A example compound according to the present disclosure includes, among other possible things, a nanodot carrier, a moiety, and a linker having first and second functional groups, wherein the first functional group is covalently linked to the nanodot carrier, and the second functional group is covalently linked to the moiety. An example method of making a nanodot carrier is also disclosed. | 2022-07-21 |
20220226510 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS - Stimuli-responsive NPs with excellent stability, high loading efficiency, encapsulation of multiple agents, targeting to certain cells, tissues or organs of the body, can be used as delivery tools. These NPs contain a hydrophobic inner core and hydrophilic outer shell, which endows them with high stability and the ability to load therapeutic agents with high encapsulation efficiency. The NPs are preferably formed from amphiphilic stimulus-responsive polymers or a mixture of amphiphilic and hydrophobic polymers or compounds, at least one type of which is stimuli-responsive. These NPs can be made so that their cargo is released primarily within target certain cells, tissues or organs of the body, upon exposure to endogenous or exogenous stimuli. The rate of release can be controlled so that it may be a burst, sustained, delayed, or a combination thereof. The NPs have utility as research tools or for clinical applications including diagnostics, therapeutics, or combination of both. | 2022-07-21 |
20220226511 | pH RESPONSIVE COMPOSITIONS AND USES THEREOF - Described herein are pH responsive compounds, micelles, and compositions useful for the detection of primary and metastatic tumor tissues. Compounds described herein are imaging agents useful for the detection of primary and metastatic tumor tissue (including lymph nodes). Real-time fluorescence imaging during surgery aids surgeon in the detection of metastatic lymph nodes or delineate tumor tissue versus normal tissue, with the goal of achieving negative margins and complete tumor resection. | 2022-07-21 |
20220226512 | MACROPHAGE IMAGING AGENT - Composite particles, each of which is obtained by forming, on the surface of a gadolinium oxide-containing particle, a cover film that contains a polymer obtained by polymerizing a monomer component containing a monomer having an ethylenically unsaturated bond; a macrophage imaging agent which contains the composite particles; and a method for producing composite particles, wherein a monomer component containing a monomer having an ethylenically unsaturated bond and gadolinium oxide-containing particles are mixed with each other, and after emulsifying the thus-obtained monomer component-containing mixture in water in the presence of a surfactant and a polymerization initiator in water, the monomer component is polymerized, thereby forming cover films on the surfaces of the gadolinium oxide-containing particles. | 2022-07-21 |
20220226513 | 18F-RADIOLABELED BIOMOLECULES - The application is drawn to | 2022-07-21 |
20220226514 | METHODS AND COMPOSITIONS FOR DETERMINING THE BIODISTRIBUTION OF ACTIVATABLE ANTI-CD166 ANTIBODY CONJUGATES - The present invention provides methods, compounds, and compositions useful for determining the in vivo distribution of a radionuclide after administering a radiolabeled activatable anti-CD166 antibody-bioactive agent conjugate to a subject by positron emission tomography imaging. The present invention also provides methods for identifying subjects suitable for treatment with the corresponding non-radiolabeled activatable anti-CD166-bioactive agent conjugates. | 2022-07-21 |
20220226515 | A STERILISATION TUNNEL OF PHARMACEUTICAL CONTAINERS - A sterilization tunnel has an inlet opening for pharmaceutical containers to be sterilised, an outlet opening, a high-temperature sterilisation chamber and a cooling chamber in line therewith and communicating with the outlet opening. A conveyor means transports the containers through the sterilisation chamber and the cooling chamber up to the outlet opening. A transfer plane is positionable in a first configuration aligned with the conveyor to transfer the containers out of the tunnel through the outlet opening. A shutter opens and closes the outlet opening. The transfer plane is movable and positionable in a second configuration inside the cooling chamber and misaligned with respect to the conveyor. When the transfer plane is inside the cooling chamber, the shutter is lowerable in abutment with a seal element. | 2022-07-21 |
20220226516 | METHOD OF STERILIZING DRINK FILLING APPARATUS AND DRINK FILLING APPARATUS - To reduce the time required to start a drink filling operation or the time interval between productions. | 2022-07-21 |
20220226517 | Location Oriented Monitoring and Sterilization System - The present invention relates to a system for and method of monitoring and sterilizing an enclosed space. A particular aspect of the invention is the use of an ultraviolet light producer. The system is controlled by and the process incorporates the use of computing technology. In summary, the invention sterilizes the applicable enclosed space by (A) monitoring the enclosed space based upon the information supplied by the computing technology, (B) sending a signal to the ultraviolet light producer to maximize the ultraviolet illumination disinfecting, and (C) using a model of the enclosed space to guide the positioning of the system throughout the disinfecting process. A final element of a general embodiment of the system would preferably be a communication element that can transmit data about the positioning of the system, and other pertinent information, to a remote device. | 2022-07-21 |
20220226518 | SANITIZATION SYSTEMS AND METHODS WITH FAR-UVC - A sanitization system for an aircraft may comprise: a power source; and a plurality of sanitizers in electrical communication with the power source, each sanitizer in the plurality of sanitizers configured to emit ultraviolet radiation having an average wavelength between 200 and 230 nm, the power source configured to provide power to each sanitizer in the plurality of sanitizers in succession during an occupied flight of the aircraft. | 2022-07-21 |
20220226519 | PUSH BUTTON UNIT - A push button unit ( | 2022-07-21 |
20220226520 | GAME MACHINE - A game machine ( | 2022-07-21 |
20220226521 | Vehicle Surfaces Sterilization Equipment - A device for sterilizing at least one surface within an interior or at an exterior of a vehicle. The surface is susceptible to exposure to micro-organisms, bacteria, pathogens and/or viruses. The device comprising: at least one UV-C light source mounted in or in the area of the surface of the object, at least one control module for controlling the UV-C light emitted by at least one UV-C light source, and at least one user presence detection module for sensing the presence of a user using the vehicle. | 2022-07-21 |
20220226522 | ULTRAVIOLET LIGHT DELIVERY APPARATUS - A portable, handheld ultraviolet light delivery apparatus for sanitization target surfaces is configured to deliver ultraviolet light at the lower end of the UVC band (i.e., having shorter wavelengths) with the majority of the ultraviolet light having a wavelength of 222 nm. The ultraviolet light delivery apparatus includes a light source positioner secured to the front side of the case where the light source positioner is configured to maintain a constant distance between the ultraviolet light source and a target surface to be sanitized. The ultraviolet light delivery apparatus further includes a timer relay that removes power from the ultraviolet light after a specified exposure duration has elapsed so as to control the dose of ultraviolet light delivered to the target surface. | 2022-07-21 |
20220226523 | APPARATUS AND METHOD FOR MODIFYING A SPRAYER BOTTLE INTO AN OZONATING AND IONIZING WATER SPRAYER BOTTLE AND FOR PROVIDING HUMIDIFICATION WITH OZONATED AND IONIZED WATER - An apparatus that can be connected to a conventional sprayer bottle that permits the sprayer bottle to generate ozonated and ionized water to be used as a cleaning fluid. The apparatus includes an ozonator element submerged in the bottle water via a first electrical conductor and an ionizer lead submerged in the water via a second electrical conductor which is connected to an ionizer that is not submerged. Respective apertures are formed in the sidewall of the bottle, each having respective electrical connectors to permit the respective electrical connections to different power sources. The dip tube of the spray head is then passed through the top opening and into the water in the bottle and the spray head is secured onto the bottle. Electrical energy is provided through the respective conductors to ozonate and ionize the water in the bottle for use a cleaning agent. Humidifier or vaporizer versions of this invention provide an ozonated and ionized water mist or vapor. | 2022-07-21 |
20220226524 | FOGGING SYSTEM AND METHODS FOR ENCLOSED CHAMBERS - A system for disinfecting an enclosed chamber may include a housing, an inlet and an outlet carried by the housing to be connected in an airflow path with the enclosed chamber, a dehumidification chamber carried by the housing, and a blower carried by the housing and connected to the airflow path between the inlet and outlet and configured to circulate air through the airflow path. The system may further include an atomizing nozzle connected to a disinfectant fluid reservoir and an air compressor and configured to atomize disinfectant within the airflow path during a treatment phase, an airflow valve connected in the airflow path between the inlet and dehumidification chamber, and a controller configured to operate the airflow valve to connect the dehumidification chamber into the airflow path during an evacuation phase and disconnect the dehumidification from the airflow path during the treatment phase. | 2022-07-21 |
20220226525 | MOBILE SANITIZATION SYSTEMS AND METHODS - A mobile sanitization system includes a movable trolley having an arm that is extendable between a first position in which the arm is in a collapsed state and a second position in which the arm is extended outwardly. The mobile sanitization system includes at least one ultraviolet light source coupled to the arm that is configured to illuminate to disinfect. The mobile sanitization system includes a source of liquid disinfectant and at least one nozzle fluidly coupled to the source of liquid disinfectant. The nozzle is coupled to at least one of the trolley and the arm, and the nozzle is configured to dispense the liquid disinfectant. The mobile sanitization system includes a spray wand removably coupled to the trolley and fluidly coupled to the source of liquid disinfectant. The spray wand is removable from the trolley to dispense the liquid disinfectant to disinfect a targeted area. | 2022-07-21 |
20220226526 | Portable sanitizing mat - The present invention is directed to a mat for enclosed spaces which has both a disinfecting and illuminating function. The mat is foldable or collapsible for stowing purposes. The inner surface includes at least a pair of UV lamps or light strips positioned thereon. The lamps, which may use UV-C radiation, are preferably powered by the local AC power. When disinfection is desired, the mat may be deployed within the enclosed space on any suitable surface and electrically connected to the AC power source. The UV lamps give off radiation which disinfects the enclosed space while unoccupied. | 2022-07-21 |
20220226527 | SPRAY BOTTLE INSERT INCLUDING CHLORINE DIOXIDE MICRO REACTOR UTILIZING MEMBRANE PACKAGING - Apparatuses for generation of a sterilizing agent, for example chlorine dioxide, in a spray bottle, methods of forming an apparatus, and methods of use thereof are provided. The apparatus may include a tube housing a packet containing a reactant disposed within the interior of the packet. The tube prevents overexpansion of the packet in the presence of an initiating agent. The apparatus may include an openable capsule that houses a packet containing a reactant disposed within the interior of the packet. The capsule includes holes for the transmission of liquid or humid air. | 2022-07-21 |
20220226528 | STERILIZATION ASSESSMENT METHODS WITH CHEMICAL INDICATORS - A class 5 chemical indicator color may be imaged such that a color of the indicator may be determined and compared to a color-value threshold indicative of an efficacious sterilization procedure. Color changes of the indicator during a sterilization procedure are typically not uniform. As such, colors on the indicator may be averaged and then compared to the color-value threshold to determine if the procedure has been efficacious or if additional exposure to a sterilant may be desired. Color values and color-value thresholds may be based on, e.g., the L*a*b* color model or a grayscale color model. | 2022-07-21 |
20220226529 | SYSTEM FOR DETERMINING ACHIEVEMENT DEGREE OF STERILIZATION PROCESS, DETERMINATION APPARATUS, MEASUREMENT APPARATUS, AND COMPUTER-READABLE STORAGE MEDIUM - A determination system includes: type determination means for acquiring determination information for determining a type of an indicator that has a discoloration area, a color of which changes according to an achievement degree of a sterilization process, and determining the type of the indicator; measurement means for measuring color information regarding the discoloration area; and achievement degree determination means for determining the achievement degree of the sterilization process based on the color information regarding the discoloration area measured by the measurement means, according to a determination criterion corresponding to the type of the indicator determined by the type determination means. | 2022-07-21 |
20220226530 | STERILIZING APPARATUS AND STERILIZING METHOD - A sterilization apparatus includes a fanner that has an inlet through which air is inhaled and an outlet from which the air is blown out and blows out a spiral air current from the outlet, an atomizer that sprays a chemical solution for sterilization into the air to be blown out from the outlet, into the spiral air current blown out from the outlet, or on a sterilization target, and a light emitter that emits light in the direction in which the spiral air current is blown out from the outlet. | 2022-07-21 |
20220226531 | UVC DURABLE FILTER - A system includes a mask having a filter. The filter is configured to capture aerosol particles. The filter may be formed from a material that is UVC durable and UVC transmissive. The system also includes a UVC LED configured to emit UVC radiation into the filter. | 2022-07-21 |
20220226532 | AIR PURIFIER - An air purifier including a body including a suction port and a discharge port, and having an inner space through which air is configured to flow from the suction port to the discharge port, a fan disposed in the inner space of the body and having a side surface separated from an inner wall of the body, a light source module including at least one UV light source disposed in the inner space of the body, a power controller mounted on the inner wall of the body, at least one filter disposed in the inner space of the body, a filter replacement region formed at the body to detachably couple the at least one filter to an interior of the body, a door detachably mounted on the body to expose the filter replacement region and including a door guide member having a groove. | 2022-07-21 |
20220226533 | PURIFIED AIR AND METHODS OF MAKING AND USING THE SAME - Purified air is provided, having a TVOC content of from less than 5 ppb to about 500 ppb, a Biologicals content of from less than 1 CFU/M | 2022-07-21 |
20220226534 | MANUFACTURING METHOD OF HIGH-EFFICIENCY PLANT COMPOSITE TYPE BACTERIOSTATIC DEODORANT BASED ON HQ22 BEAN EXTRACT - The manufacturing method of high-efficiency plant composite type bacteriostatic deodorant based on HQ22 bean extract includes pretreating the leaves of certain beans and certain plants in the early stage, which are then respectively processed into powder by a pulverizer; uniformly mixing the two powders according to a certain mass ratio, which are then treated with inoculation process with a certain inoculation amount of | 2022-07-21 |
20220226535 | DISINFECTION SYSTEM OF CONTACT LENS - A disinfection system of a contact lens comprising immersing the contact lens in a disinfecting solution containing hydrogen peroxide in a concentration of 1 to 10% and neutralizing the hydrogen peroxide in the disinfecting solution through contact with a metal catalyst, where the disinfecting solution contains an organic carboxylic acid or a salt of the organic carboxylic acid, the organic carboxylic acid having a structure in which a hydroxyl group and a carboxyl group are bonded to one carbon atom; the disinfecting solution is adjusted to have a pH of 6 to 8; and the disinfecting solution after the neutralization is adjusted to have an osmotic pressure of 250 to 350 mOsm. | 2022-07-21 |
20220226536 | WOUND CONTACT LAYER AND DRESSING FOR IODINE DELIVERY - Disclosed embodiments relate to a wound contact layer in the form of a perforated film, possessing one or more of the following functions: speed of kill, sustained kill, broad-spectrum kill against microorganisms, one-piece removal, conformability with a wound surface, compatibility with negative pressure wound treatment, exudate management, autolytic debridement, and self-indicating of changes. The wound contact layer comprises a biocompatible polymeric matrix and, embedded in the matrix, fluid-absorbent particles loaded with therapeutics. The matrix comprises a mixture of an elastomeric composition and a hydrophilic polymer. The film is perforated with an array of holes. A desired loading of therapeutics in the wound contact layer may be tuned by varying the amount of therapeutics loaded within the fluid-absorbent particles, the density of the fluid-absorbent particles within the wound contact layer, the perforation size, and the thickness of the wound contact layer. | 2022-07-21 |
20220226537 | Nanofiber Structures and Methods of Use Thereof - Coated and expanded, nanofiber structures are provided and methods of use thereof. | 2022-07-21 |
20220226538 | COMPOSITION FOR TRANSPLANTATION OF ORGANOID - The present invention relates to a composition for transplantation comprising an organoid, and a use of same. According to one example, using collagen, gelatin or fibrin glue as a scaffold for organoid transplantation results in a high transplantation rate and a high survival rate of organoid as well as desirable stability. | 2022-07-21 |
20220226539 | COMPOSITE SCAFFOLD CONTAINING DFO AND RHBMP-2, PREPARATION METHOD AND USE THEREOF - The present disclosure relates to a composite scaffold containing DFO and rhBMP-2 capable of synergistically stimulating bone formation, a preparation method and use thereof. The composite scaffold contains a matrix, a PEGS gel layer and rhBMP-2, wherein the matrix is an MBG scaffold grafted with DFO on the surface, the PEGS gel layer is carried on the surface of the matrix, and rhBMP-2 is carried inside the PEGS gel layer. In the present disclosure, the function of DFO and rhBMP-2 in vivo and in vitro can be regulated by precisely controlling the immobilization mode and spatial distribution of DFO and rhBMP-2 in the scaffold, and the all-round repair of “rapid enrichment of target cells—angiogenesis-guided bone” can be achieved. | 2022-07-21 |
20220226540 | BIOMEDICAL COMPOSITE MATERIAL AND PREPARATION METHOD THEREFOR - The present invention relates to an absorbable biomedical composite material and a preparation method therefor, wherein the absorbable biomedical composite material comprises: a substrate particle containing a calcium phosphate compound; an intermediate layer which is coated on the surfaces of the substrate particle and has a first glass transition temperature, the first glass transition temperature being not higher than a normal body temperature; and a polymer matrix which is formed on the outer surface of the intermediate layer and has a second glass transition temperature, the second glass transition being higher than the first glass transition temperature. The present invention can provide an absorbable biomedical composite material which not only increases the mechanical strength but also improves the toughness. | 2022-07-21 |
20220226541 | AN ABSORBABLE BIOMEDICAL POLYLACTIC ACID COMPOSITE MATERIAL AND PREPARATION METHOD THEREFOR - The present invention relates to an absorbable biomedical composite material and a preparation method therefor, wherein the absorbable biomedical composite material comprises: a substrate particle containing a calcium phosphate compound; an intermediate layer which is coated on the surfaces of the substrate particle and has a first glass transition temperature, the first glass transition temperature being not higher than a normal body temperature; and a polymer matrix which is formed on the outer surface of the intermediate layer and has a second glass transition temperature, the second glass transition being higher than the first glass transition temperature. The present invention can provide an absorbable biomedical composite material which not only increases the mechanical strength but also improves the toughness. | 2022-07-21 |
20220226542 | COMPOSITIONS AND METHODS FOR PROMOTING PATENCY OF VASCULAR GRAFTS - Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the vascular grafts, thus avoiding many problems associated with cell seeding. Biodegradable, polymeric vascular grafts which provide controlled release of cytokines and/or chemokines at the site of vascular graft implantation are also provided. | 2022-07-21 |
20220226543 | Patterned Hydrogel Devices and Methods for Neural Regeneration - A matrix for neuron regeneration. The matrix can include a sheet having a first surface and a second surface opposite the first surface, the second surface having a plurality of integrally formed ridges. The sheet can have a spiral shape, such that the first surface of the sheet faces the second surface of the sheet. The sheet and the integrally formed ridges can comprise oligo(poly(ethylene glycol) fumarate). | 2022-07-21 |
20220226544 | JOINT IMPLANT WITH CONSTANT AND CONTINUOUS RELEASE OF THERAPEUTIC AGENT - Provided herein are devices and methods for treating inflammation and pain of articular joints (e.g., the knee). An implantable device includes an elongate body extending from a proximal end to a distal end, a flange disposed at the proximal end, a bore extending from an opening at the proximal end into the elongate body, one or more fixation members disposed on an outer surface of the elongate body, and a payload (e.g., a drug-polymer core) having a therapeutic agent disposed within the bore. The payload has a substantially constant surface area on an exposed portion throughout elution of the therapeutic agent after the implantable device is implanted in a body. The therapeutic agent is configured to elute using zero-order kinetics, constantly and continuously at an amount that is above a predetermined lower threshold and does not exceed a predetermined upper threshold unlike a pulse-dose injection. | 2022-07-21 |
20220226545 | METHODS OF COATING ANTIMICROBIAL PEPTIDES ON THE BIOMATERIAL AND THE BIOMATERIAL COATED THEREBY - The present invention pertains to methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby. The coating solution described herein comprises one or more antimicrobial peptides (AMPs) dissolved in a buffer containing an anionic surfactant, wherein the AMPs are amphipathic and cationic. | 2022-07-21 |
20220226546 | SURFACE COATING STRUCTURE OF SURGICAL PROSTHESIS AND METHOD FOR MODIFYING SURFACE OF SURGICAL PROSTHESIS USING SAME - A surface coating structure of a surgical prosthesis according to an exemplary embodiment of the present disclosure may include: a first coating layer formed on the surface of the surgical prosthesis and including an amino compound for surface adhesion; a second coating layer formed on one side of the first coating layer and including a fluorine compound conferring hydrophobicity to the surface coating structure of the surgical prosthesis; and a third coating layer formed on one side of the second coating layer and including a lubricant component for preventing adhesion of a biomaterial existing in a subject into which the surgical prosthesis is inserted. | 2022-07-21 |
20220226548 | METAL MATERIAL HAVING BIOLOGICAL PROPERTIES - Aspects of the invention relate to a metal material and product made from the metal material having biological properties, such as antibiotic properties. | 2022-07-21 |
20220226549 | COMPOSITIONS AND DEVICES INCORPORATING WATER-INSOLUBLE THERAPEUTIC AGENTS AND METHODS OF THE USE THEREOF - Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions. | 2022-07-21 |
20220226550 | Filter Assembly and Container for Collecting a Body Fluid Containing the Same - A filter assembly for filtering a body fluid comprising a filter system and a filter holder is disclosed, wherein the filter system consists of at least two layers. The first layer is a defoaming layer made of a monofilament woven open mesh fabric and with an embossed three dimensional structure configured for entrapping foam built up in the body fluid. The second layer is a mesh filter layer, and is arranged downstream of the defoaming layer. A container for collecting a body fluid comprising such a filter assembly is also disclosed. | 2022-07-21 |
20220226551 | HEMODIALYSIS SYSTEM INCLUDING A DISPOABLE SET AND A DIALYSIS INSTRUMENT - A hemodialysis system is disclosed. The hemodialysis system includes a dialyzer, a saline container including saline, and a disposable set comprising a blood pumping tube fluidly connected to a first end of the dialyzer, an arterial line fluidly connected to a first end of the blood pumping tube, a venous line fluidly connected to a second end of the dialyzer, a saline line fluidly connected to the blood pumping tube and the saline container, and a dialyzer line fluidly connected to a second end of the blood pumping tube and a second end of the dialyzer. The hemodialysis system also includes a dialysis instrument comprising an arterial line clamp, a venous line clamp, and a saline valve. The saline rinses blood out of the arterial line when the venous line clamp is closed, the arterial line clamp is opened, and the saline value is opened. | 2022-07-21 |
20220226552 | AUTOMATIC RECHARGER BRINE PREPARATION FROM A SALT CARTRIDGE - The disclosure relates to systems and methods for generating a brine solution using a salt cartridge for recharging zirconium phosphate in a reusable sorbent module. The salt cartridge can include an inlet and an outlet on opposite sides. Water can be pumped through the salt cartridge to dissolve the salts in the salt cartridge and the resulting solution can be collected as a brine solution for use in recharging the zirconium phosphate. | 2022-07-21 |
20220226553 | HEMODIALYSIS ENHANCEMENT APPARATUS & METHOD - A hemodialysis enhancement apparatus involves a bladder having elastically deformable surface that forms a variable volume therewithin. The elastically deformable surface has a smooth interior surface such that blood cannot collect to form a blood clot. The hemodialysis enhancement apparatus further includes a rigid housing having a wall surrounding the bladder and defining a housing volume such that a) when the variable volume chamber has a volume equal to the first volume, most of the elastically deformable surface will be spaced apart from the wall, and b) when the variable volume chamber has a volume equal to the second volume, a substantial portion of the elastically deformable surface will abut the wall. A method performed within a hemodialysis system involves, during an initial phase, withdrawing a volume of a patient's blood into a hemodialysis enhancer, and during a subsequent phase, translocating the patient's blood back into the patient's circulation. | 2022-07-21 |
20220226554 | OXYGEN SUPPLYING APPARATUS HAVING CIRCULATION FACILITATING - An oxygen supply apparatus is configured to directly supply oxygen-containing gas to an user for inhalation while facilitating blood circulation of a specific portion of the user. The oxygen supply apparatus includes a power supply; an oxygen-containing gas source for providing the oxygen-containing gas; a gas catheter having one end thereof connected to the oxygen-containing gas source; an inhalator connected to the other end of the gas catheter; and a circulation facilitating device at least partially attached to the specific portion of the user. The circulation facilitating device includes a sonic oscillation circuit and a housing. The sonic oscillation circuit is configured to produce oscillation at a frequency ranging from 20 Hz to 10 MHz, and the housing encloses the sonic oscillation circuit in a watertight manner | 2022-07-21 |
20220226555 | MANUAL CLOT ASPIRATION AND FILTRATION SYSTEM AND METHOD OF REMOVING A CLOT - A manual clot aspiration and filtration system enables a method of removing a clot without general anesthesia and the expense of an operating room. An aspiration and filtration system for bodily fluid utilizes a syringe coupled with a filter unit to draw bodily fluid through the filter unit to collect debris on the filter. A flow valve may then be turned and the plunger depressed to force the filtered fluid back into the body. The filter may be configured to capture particles such as blood clots and plaque. The filter unit has a cover that can be removed for inspection and/or removal of the collected debris. When the cover is replaced, trapped air may be removed by turning the flow-valve to a purge direction and pressing the plunger into the syringe to force fluid back toward the filter unit to purge the trapped air through the purge valve. | 2022-07-21 |
20220226556 | Shunts with blood-flow indicators - An apparatus for shunting blood includes a flow-indication chamber shaped to define an entry port and an exit port, and one or more moveable objects disposed within the flow-indication chamber and configured to move in response to a flowing of the blood from the entry port to the exit port. At least a portion of a wall of the flow-indication chamber is transparent so as to expose the moveable objects to sight. Other embodiments are also described. | 2022-07-21 |
20220226557 | COLLECTION SYSTEM FOR MANAGING OUTFLOW FROM A SURGICAL PROCEDURE - A fluid collection system includes a vacuum source, a collection vessel, and a surgical drape. A fluid outflow line is connected between the surgical drape and the collection vessel. The fluid outflow line provides a path for fluid to the collection vessel. A suction line is connected with the collection vessel. The suction line provides suction to draw fluid through the fluid outflow line to the collection vessel. The suction line branches into a first suction line and a second suction line parallel with the first suction line. The first suction line and the second suction line are each connected with the vacuum source. A flow restrictor is disposed along the first suction line. A valve is disposed along the second suction line. The valve is opened in a pulsatile fashion when fluid is present in the surgical drape to increase a level of suction provided to the surgical drape. | 2022-07-21 |
20220226558 | Bone Material Harvesting Device - A bone harvesting device includes a main body having an internal cavity and a suction port adapted to be coupled to a suction source. The device further includes an outer tube ( | 2022-07-21 |
20220226559 | WIRELESS SYSTEM TO ENABLE AUTO-DETERMINATION OF APPLICATION SPECIFIC THERAPY DEVICE SCREENS AND SETTING OPTIONS - A system for wirelessly controlling a dressing interface that performs negative pressure wound therapy and fluid instillation therapy at a wound site. The system comprises a core module comprising: i) a plurality of sensors configured to determine a plurality of physical parameter data associated with the wound site; ii) a processor coupled to the plurality of sensors and configured to read the physical parameter data from the plurality of sensors; iii) a wireless transceiver coupled to the processor and configured to communicate with an external therapy controller; and iv) at least a first internal peripheral device coupled to the processor. The system further comprises at least a first external peripheral interface coupled to the core module and configured to communicate with the processor, wherein the core module and the at least a first external peripheral interface are disposed within a housing of the dressing interface. | 2022-07-21 |